New Evidence Early Tx Improves Preclinical MS Outcomes
TOPLINE: The disease-modifying treatment (DMT) delays conversion to clinical multiple sclerosis (MS) for patients with radiologically isolated syndrome (RIS) and has a reassuring long-term safety profile, […]
Read more